B. Gan

The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib.

T. Mok, Yi-long Wu, S. An, 2007, European journal of pharmacology.

A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study

Ying Cheng, Yi-long Wu, B. Han, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

2021年非小细胞肺癌重要临床研究纵观与解读

Yilong Wu, S. Liu, B. Gan, 2022, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma

K. Do, E. Jonasch, K. Shaw, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Yi-long Wu, Jin-Ji Yang, S. Chuai, 2017, Clinical Cancer Research.

Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2019, EBioMedicine.

Biomarker-integrated study of single agent targeting molecular alterations of PI3KCA, MET, ALK, ROS1, KRAS, NRAS or BRAF in advanced NSCLC: Phase 2 umbrella trial in China (CTONG1505).

Y. Wu, H-J. Chen, A. Myers, 2018, Annals of Oncology.